HLS Therapeutics Inc. (HLS.TO)
| Previous Close | 4.6500 |
| Open | 4.7000 |
| Bid | 4.6500 x 0 |
| Ask | 4.7800 x 0 |
| Day's Range | 4.7000 - 4.7500 |
| 52 Week Range | 3.3400 - 7.1200 |
| Volume | |
| Avg. Volume | 9,611 |
| Market Cap | 151.459M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.20 (4.30%) |
| Ex-Dividend Date | Apr 27, 2023 |
| 1y Target Est | N/A |
- CNW Group
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday, May 9, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. John Hanna, Interim Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
- CNW Group
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place April 16-17, 2024 at the Metro Toronto Convention Centre, North Building, in downtown Toronto.
- CNW Group
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today highlighted two data presentations at the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular Events (MACE) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as r
